 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456» |
- ||| Signifor (pasireotide) / Recordati
Trial completion, Trial primary completion date, Combination therapy: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (clinicaltrials.gov) - May 22, 2020
P2, N=68, Completed, Sponsor: Novartis Pharmaceuticals
Terminated --> Completed | Trial primary completion date: Sep 2016 --> Sep 2019
- |||| Lutathera (lutetium Lu 177 dotatate) / Novartis
Trial completion date, Trial primary completion date, Metastases: NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) - Mar 12, 2020
P3, N=222, Recruiting, Sponsor: Advanced Accelerator Applications
Terminated --> Completed | Trial primary completion date: Sep 2016 --> Sep 2019 Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Feb 2022 --> Dec 2023
- ||||| Signifor (pasireotide) / Recordati
Trial completion date, Trial termination, Combination therapy: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (clinicaltrials.gov) - Mar 11, 2020
P2, N=68, Terminated, Sponsor: Novartis Pharmaceuticals
Trial completion date: Feb 2026 --> Dec 2026 | Trial primary completion date: Feb 2022 --> Dec 2023 Trial completion date: Dec 2019 --> Sep 2019 | Active, not recruiting --> Terminated
- | Signifor (pasireotide) / Recordati
New trial: Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections (clinicaltrials.gov) - Feb 24, 2020
P, N=258, Completed, Sponsor: Helsinki University Central Hospital
- |||||| Lutathera (lutetium Lu 177 dotatate) / Novartis
Enrollment open, Metastases: NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) - Feb 18, 2020
P3, N=222, Recruiting, Sponsor: Advanced Accelerator Applications
Trial completion date: Dec 2019 --> Sep 2019 | Active, not recruiting --> Terminated Not yet recruiting --> Recruiting
- | Signifor (pasireotide) / Recordati
Trial completion date: Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease (clinicaltrials.gov) - Feb 5, 2020
P=N/A, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Sep 2023 --> May 2024
- ||||| Lutathera (lutetium Lu 177 dotatate) / Novartis
Trial initiation date, Trial primary completion date, Metastases: NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) - Jan 7, 2020
P3, N=222, Not yet recruiting, Sponsor: Advanced Accelerator Applications
Trial completion date: Sep 2023 --> May 2024 Initiation date: Nov 2019 --> Jan 2020 | Trial primary completion date: Dec 2022 --> Feb 2022
- | Signifor (pasireotide) / Recordati
Trial completion: Pasireotide in Prevention of GI Toxicity (clinicaltrials.gov) - Nov 14, 2019
P2, N=37, Completed, Sponsor: Anthony Sung, MD
Initiation date: Nov 2019 --> Jan 2020 | Trial primary completion date: Dec 2022 --> Feb 2022 Active, not recruiting --> Completed
- ||| Signifor (pasireotide) / Recordati
Enrollment open, Enrollment change: A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 (clinicaltrials.gov) - Nov 7, 2019
P1, N=176, Recruiting, Sponsor: Heptares Therapeutics Limited
Active, not recruiting --> Completed Active, not recruiting --> Recruiting | N=120 --> 176
- | Lutathera (lutetium Lu 177 dotatate) / Novartis
Trial initiation date, Metastases: NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) - Sep 26, 2019
P3, N=222, Not yet recruiting, Sponsor: Advanced Accelerator Applications
Active, not recruiting --> Recruiting | N=120 --> 176 Initiation date: Aug 2019 --> Nov 2019
- | Signifor (pasireotide) / Recordati
Trial completion date, Trial primary completion date: A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 (clinicaltrials.gov) - Aug 7, 2019
P1, N=120, Active, not recruiting, Sponsor: Heptares Therapeutics Limited
Initiation date: Aug 2019 --> Nov 2019 Trial completion date: Oct 2019 --> Apr 2020 | Trial primary completion date: Jul 2019 --> Mar 2020
- | Signifor (pasireotide) / Recordati
Trial completion date, Trial primary completion date: Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia (clinicaltrials.gov) - Jul 10, 2019
P1, N=1, Recruiting, Sponsor: University of Colorado, Denver
Trial completion date: Oct 2019 --> Apr 2020 | Trial primary completion date: Jul 2019 --> Mar 2020 Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2019 --> Mar 2022
- |||||||||| Lutathera (lutetium Lu 177 dotatate) / Novartis
New P3 trial, Metastases: NETTER-2: Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET (clinicaltrials.gov) - Jun 2, 2019
P3, N=222, Not yet recruiting, Sponsor: Advanced Accelerator Applications
- || Signifor (pasireotide) / Recordati
Enrollment closed: A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 (clinicaltrials.gov) - May 6, 2019
P1, N=120, Active, not recruiting, Sponsor: Heptares Therapeutics Limited
Trial completion date: Mar 2019 --> Mar 2022 | Trial primary completion date: Mar 2019 --> Mar 2022 Recruiting --> Active, not recruiting
- | Signifor (pasireotide) / Recordati
Enrollment closed, Surgery: HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications (clinicaltrials.gov) - Mar 5, 2019
P4, N=125, Active, not recruiting, Sponsor: Helsinki University Central Hospital
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Signifor (pasireotide) / Recordati
Enrollment open: A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 (clinicaltrials.gov) - Feb 25, 2019
P1, N=120, Recruiting, Sponsor: Heptares Therapeutics Limited
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| Signifor (pasireotide) / Recordati
New P1 trial: A Study in Healthy Subjects to Assess the Safety, Tolerability, PK and PD of HTL0030310 (clinicaltrials.gov) - Feb 20, 2019
P1, N=120, Not yet recruiting, Sponsor: Heptares Therapeutics Limited
- ||| Signifor (pasireotide) / Recordati
Trial termination: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache (clinicaltrials.gov) - Feb 18, 2019
P2, N=28, Terminated, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Completed --> Terminated; Novartis decision based on Cohort 1 results
- ||| Signifor (pasireotide) / Recordati
Trial completion, Enrollment change: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache (clinicaltrials.gov) - Feb 5, 2019
P2, N=28, Completed, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; Novartis decision based on Cohort 1 results Recruiting --> Completed | N=60 --> 28
- | Signifor (pasireotide) / Recordati
Enrollment closed, Trial completion date: Pasireotide in Prevention of GI Toxicity (clinicaltrials.gov) - Jan 24, 2019
P2, N=37, Active, not recruiting, Sponsor: Anthony Sung, MD
Recruiting --> Completed | N=60 --> 28 Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Oct 2019
- | Signifor (pasireotide) / Recordati
Trial completion, Trial completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Oct 18, 2018
P1, N=13, Completed, Sponsor: Emory University
Recruiting --> Active, not recruiting | Trial completion date: Jan 2020 --> Oct 2019 Trial completion date: Mar 2019 --> Oct 2018 | Active, not recruiting --> Completed
- | Signifor (pasireotide) / Recordati
Trial completion date, Trial primary completion date: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache (clinicaltrials.gov) - Aug 23, 2018
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2019 --> Oct 2018 | Active, not recruiting --> Completed Trial completion date: Jun 2021 --> Dec 2018 | Trial primary completion date: Jun 2021 --> Dec 2018
- | Signifor (pasireotide) / Recordati
Trial completion date, Trial primary completion date: Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease (clinicaltrials.gov) - Aug 20, 2018
P=N/A, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jun 2021 --> Dec 2018 | Trial primary completion date: Jun 2021 --> Dec 2018 Trial completion date: May 2024 --> Sep 2023 | Trial primary completion date: May 2024 --> Sep 2023
- | Signifor (pasireotide) / Recordati
Enrollment open, Surgery, Bariatric surgery: Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery (clinicaltrials.gov) - Jul 5, 2018
P4, N=5, Enrolling by invitation, Sponsor: Zealand University Hospital
Trial completion date: May 2024 --> Sep 2023 | Trial primary completion date: May 2024 --> Sep 2023 Not yet recruiting --> Enrolling by invitation
- Signifor (pasireotide) / Recordati
Trial withdrawal: Pasireotide in Hyperinsulinemic Hypoglycemia (clinicaltrials.gov) - Jun 18, 2018
P2, N=0, Withdrawn, Sponsor: Montefiore Medical Center
Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Withdrawn
- | Signifor (pasireotide) / Recordati
New P4 trial, Surgery, Bariatric surgery: Pasireotide in the Treatment of Hypoglycemia Following Gastric Bypass Surgery (clinicaltrials.gov) - May 1, 2018
P4, N=5, Not yet recruiting, Sponsor: Zealand University Hospital
- | Victoza (liraglutide) / Novo Nordisk, Signifor (pasireotide) / Recordati, Januvia (sitagliptin) / Merck (MSD)
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Surgery, Bariatric surgery: Treatment of Hypoglycemia Following Gastric Bypass Surgery (clinicaltrials.gov) - Mar 7, 2018
P4, N=11, Completed, Sponsor: Zealand University Hospital
Not yet recruiting --> Withdrawn Enrolling by invitation --> Completed | N=16 --> 11 | Trial completion date: Feb 2018 --> Apr 2017 | Trial primary completion date: Dec 2017 --> Apr 2017
- || Signifor (pasireotide) / Recordati
Trial completion date, Trial initiation date, Trial primary completion date: Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease (clinicaltrials.gov) - Mar 3, 2018
P=N/A, N=200, Recruiting, Sponsor: Novartis Pharmaceuticals
Enrolling by invitation --> Completed | N=16 --> 11 | Trial completion date: Feb 2018 --> Apr 2017 | Trial primary completion date: Dec 2017 --> Apr 2017 Trial completion date: Apr 2024 --> May 2024 | Initiation date: Mar 2013 --> Mar 2013 | Trial primary completion date: Apr 2024 --> May 2024
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Trial completion date, Trial initiation date, Trial primary completion date: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Mar 2, 2018
P4, N=400, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Apr 2024 --> May 2024 | Initiation date: Mar 2013 --> Mar 2013 | Trial primary completion date: Apr 2024 --> May 2024 Trial primary completion date: Jul 2024 --> Jun 2023 | Trial completion date: Jul 2024 --> Jun 2023 | Initiation date: Dec 2012 --> Jan 2013
- Signifor (pasireotide) / Recordati
Enrollment change, Trial withdrawal: SOM230 Ectopic ACTH-producing Tumors (clinicaltrials.gov) - Jan 26, 2018
P2, N=0, Withdrawn, Sponsor: Cedars-Sinai Medical Center
Trial primary completion date: Jul 2024 --> Jun 2023 | Trial completion date: Jul 2024 --> Jun 2023 | Initiation date: Dec 2012 --> Jan 2013 N=16 --> 0 | Recruiting --> Withdrawn
- || Signifor (pasireotide) / Recordati
Trial primary completion date: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache (clinicaltrials.gov) - Jan 25, 2018
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
N=16 --> 0 | Recruiting --> Withdrawn Trial primary completion date: Jan 2019 --> Jun 2021
- || Signifor (pasireotide) / Recordati
Trial primary completion date, Combination therapy: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (clinicaltrials.gov) - Nov 30, 2017
P2, N=70, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2019 --> Jun 2021 Trial primary completion date: Dec 2019 --> Sep 2016
- Signifor (pasireotide) / Recordati
Trial primary completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 22, 2017
P1, N=13, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2019 --> Sep 2016 Trial primary completion date: Dec 2017 --> Dec 2018
- || Signifor (pasireotide) / Recordati
Trial primary completion date, Combination therapy: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (clinicaltrials.gov) - Nov 14, 2017
P2, N=70, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2017 --> Dec 2019
- || Signifor (pasireotide) / Recordati
Trial primary completion date: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache (clinicaltrials.gov) - Sep 11, 2017
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2017 --> Dec 2019 Trial primary completion date: Dec 2019 --> Jan 2019
- | Signifor (pasireotide) / Recordati
Phase classification, Enrollment change, Trial termination: Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor (clinicaltrials.gov) - Aug 14, 2017
P1/2, N=7, Terminated, Sponsor: New York University School of Medicine
Phase classification: P2 --> P1/2 | N=12 --> 7 | Completed --> Terminated; PI has passed away. Requested by department to terminate study.
- Signifor (pasireotide) / Recordati
New P1 trial: Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia (clinicaltrials.gov) - Apr 5, 2017
P1, N=1, Recruiting, Sponsor: University of Colorado, Denver
- | Signifor (pasireotide) / Recordati
New P4 trial: Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment (clinicaltrials.gov) - Mar 14, 2017
P4, N=24, Completed, Sponsor: University of Palermo
- ||||||| Signifor (pasireotide) / Recordati
Trial completion: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (clinicaltrials.gov) - Mar 1, 2017
P3, N=104, Completed, Sponsor: Novartis Pharmaceuticals
Requested by department to terminate study. Active, not recruiting --> Completed
- Signifor (pasireotide) / Recordati
New P2 trial: Pasireotide in Hyperinsulinemic Hypoglycemia (clinicaltrials.gov) - Feb 15, 2017
P2, N=4, Not yet recruiting, Sponsor: Montefiore Medical Center
- ||| Signifor LAR (pasireotide long acting release) / Recordati
Trial initiation date: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies (clinicaltrials.gov) - Jan 4, 2017
P4, N=400, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Initiation date: Jun 2013 --> Dec 2012
- Signifor (pasireotide) / Recordati
Trial primary completion date, Metastases: Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer (clinicaltrials.gov) - Dec 6, 2016
P1/2, N=24, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Initiation date: Jun 2013 --> Dec 2012 Trial primary completion date: Aug 2016 --> Mar 2017
- Signifor (pasireotide) / Recordati
Enrollment open, Surgery: HYPAR Trial - Hydrocortisone vs. Pasireotide in Reducing Pancreatic Surgery Complications (clinicaltrials.gov) - Dec 6, 2016
P4, N=124, Recruiting, Sponsor: Helsinki University Central Hospital
Trial primary completion date: Aug 2016 --> Mar 2017 Not yet recruiting --> Recruiting
- || Signifor (pasireotide) / Recordati
Trial primary completion date, Combination therapy: Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease (clinicaltrials.gov) - Nov 29, 2016
P2, N=69, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Dec 2017
- Signifor (pasireotide) / Recordati
Trial primary completion date: Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (clinicaltrials.gov) - Nov 18, 2016
P1, N=13, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- |||| Signifor (pasireotide) / Recordati
Enrollment open, Trial primary completion date: Safety and Efficacy Study of SOM230 s.c. in Cluster Headache (clinicaltrials.gov) - Nov 10, 2016
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2016 --> Dec 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2018 --> Dec 2019
- ||| Signifor (pasireotide) / Recordati
Trial completion date: An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. (clinicaltrials.gov) - Nov 7, 2016
P3, N=104, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Trial primary completion date: Jun 2018 --> Dec 2019 Trial completion date: Sep 2016 --> Dec 2016
- | Signifor (pasireotide) / Recordati
Trial completion: A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease (clinicaltrials.gov) - Nov 6, 2016
P2, N=26, Completed, Sponsor: Novartis Pharmaceuticals
Trial completion date: Sep 2016 --> Dec 2016 No longer recruiting --> Completed
- |||| Signifor (pasireotide) / Recordati
Trial completion: Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients (clinicaltrials.gov) - Nov 6, 2016
P2, N=62, Completed, Sponsor: Novartis Pharmaceuticals
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Signifor (pasireotide) / Recordati
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors (clinicaltrials.gov) - Oct 19, 2016
P1, N=22, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=32 --> 22 | Trial primary completion date: Apr 2016 --> Sep 2014